Company Balance Sheet at 31 December AstraZeneca PLC 2017 2016 Notes $m $m Fixed assets Fixed asset investments 1 31,482 30,449 Current assets Debtors other 11 14 Debtors amounts owed by Group undertakings 7,995 8,935 8,006 8,949 Creditors: Amounts falling due within one year Non-trade creditors 2 518 325 Interest-bearing loans and borrowings 3 1,749 1,397 1,722 2,267 Net current assets 6,284 6,682 Total assets less current liabilities 37,766 37,131 Creditors: Amounts falling due after more than one year Amounts owed to Group undertakings 3 283 283 Interest-bearing loans and borrowings 3 15,197 14,138 15,480 14,421 22,710 Net assets 22,286 Capital and reserves Called-up share capital 4 317 316 Share premium account 4,393 4,351 Capital redemption reserve 153 153 Other reserves 2,549 2,583 Profit and loss account 14,874 15,307 Shareholders funds 22,286 22,710 $m means millions of US dollars.
The Companys profit for the year was $3,109m 2016: $3,699m.
The Company Financial Statements from page 194 to 198 were approved by the Board on 2 February 2018 and were signed on its behalf by Pascal Soriot Marc Dunoyer Director Director Companys registered number 02723534 194 AstraZeneca Annual Report & Form 20-F Information 2017 Financial Statements Financial Statements Statement of Changes in Equity For the year ended 31 December Share Capital Share premium redemption Other Profit and Total capital account reserve reserves loss account equity $m $m $m $m $m $m At 1 January 2016 316 4,304 153 2,623 15,147 22,543 Total comprehensive income for the period Profit for the period 3,699 3,699 Amortisation of loss on cash flow hedge 1 1 Total comprehensive income for the period 3,700 3,700 Transactions with owners, recorded directly in equity Dividends 3,540 3,540 Capital contributions for share-based payments 40 40 Issue of Ordinary Shares 47 47 Total contributions by and distributions to owners 47 40 3,540 3,533 316 4,351 153 2,583 15,307 22,710 At 31 December 2016 Total comprehensive income for the period Profit for the period 3,109 3,109 Amortisation of loss on cash flow hedge 1 1 Total comprehensive income for the period 3,110 3,110 Transactions with owners, recorded directly in equity Dividends 3,543 3,543 Capital contributions for share-based payments 34 34 Issue of Ordinary Shares 1 42 43 Total contributions by and distributions to owners 1 42 34 3,543 3,534 At 31 December 2017 317 4,393 153 2,549 14,874 22,286 At 31 December 2017, $14,874m 2016: $15,307m of the profit and loss account reserve was available for distribution.
Included in other reserves is a special reserve of $157m 2016: $157m, arising on the redenomination of share capital in 1999.
Included within other reserves at 31 December 2017 is $708m 2016: $742m in respect of cumulative share-based payment awards.
These amounts are not available for distribution.
AstraZeneca Annual Report & Form 20-F Information 2017 Company Statements 195
